Vaccines are one of the most cost effective and powerful health interventions available. Billions of people from around the world are successfully being protected from various diseases through these vaccines. In particular, vaccines have helped saving the lives of around three million children each year, and have significantly reduces diseases, disability, and death globally.
Diseases like polio, meningococcal disease, seasonal influenza, viral hepatitis, HPV and RSV are those with the most vaccines on the market.
Pharmaceutical companies, both large and small, are spending high in vaccine R&D. Companies like Sanofi and GSK possess a large number of vaccines in their diverse portfolios, larger-than-average pipelines, and a relatively wide geographic spread.
Market of Vaccines
The worldwide vaccine market experienced rapid growth in 2016. During this year, global vaccines sale reached $27.5bn, which was 3.4% of the worldwide market share. GSK, Merck & Co, Pfizer, and Sanofi were the market leaders in 2016, and shared 88% of the total vaccine market share globally.
The sales of pneumococcal vaccine from Pfizer and Daewoong, Prevnar 13, reached $6.0bn in 2016, which was the best-selling vaccine in that year. The worldwide market share of Prevnar 13 was 21.9%. Merck & Co. also dominated this market with its human papillomavirus (HPV) vaccine Gardasil. The company earned $2.4bn in this year through selling Gardasil. Sanofi were also in the top position in 2016 with the $1.7bn sales of its prominent DTaP, Hib & polio vaccine Pentacel, and $1.8bn sales of its influenza vaccine Fluzone. Furthermore, GSK earned $524m through its meningococcal b vaccine Bexsero.
Various factors have contributed toward the rapid growth of the vaccine market. These include: more stringent governmental recommendations and growing awareness from common people. However, high costs associated with R&D and strict regulatory approval processes are working as the major limiting factors for this growth.
Luca Dezzani is a Novartis employee. All the views, analysis, and perspectives are fully independent and belongs to the author only. They do not represent the views or opinions of Novartis or any other company or organization. IgeaHub is a pharmaceutical blog created and curated by Luca Dezzani. IgeaHub does not receive any funding or support from Novartis or any other pharmaceutical company.